Quick Answer
Silo Pharma, Inc. reported Cash and Equivalents of $4.75 million for fiscal year 2025.
Silo Pharma, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $4.75M | +21.6% |
| 2024 | $3.91M | +10.8% |
| 2023 | $3.52M | -69.0% |
| 2022 | $11.37M | +15.6% |
| 2021 | $9.84M | +771.8% |
| 2020 | $1.13M | +909.7% |
| 2019 | $111.8K | -66.8% |
| 2018 | $336.7K | +14.3% |
| 2017 | $294.6K | -49.1% |
| 2016 | $579.2K | -71.2% |
| 2013 | $2.01M | +720552.3% |
| 2012 | $279.00 | -84.1% |
| 2011 | $1.8K | -96.3% |
| 2010 | $47.5K | — |
| 2010 | $0.00 | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $3.92M | -19.4% | -9.6% |
| June 30, 2025 | $4.33M | -3.8% | +38.2% |
| March 31, 2025 | $3.14M | +17.6% | -19.7% |
| December 31, 2024 | $3.91M | +10.8% | -19.6% |
| September 30, 2024 | $4.86M | +2332.4% | +7.9% |
| June 30, 2024 | $4.51M | +2737.1% | +68.9% |
| March 31, 2024 | $2.67M | -42.8% | -24.3% |
| December 31, 2023 | $3.52M | -69.0% | +1663.6% |
- Silo Pharma, Inc. showed an increase of +21.6% in Cash and Equivalents compared to the prior fiscal year.
- The most recent figure is from Silo Pharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: